news
First patient treated in Phase I VXM01 glioblastoma trial
Vaximm's VXM01 is an oral T-cell immunotherapy that targets the tumour-specific vasculature and certain immune-suppressive cells...
List view / Grid view
Victoria White (European Pharmaceutical Review)
news
Pfizer completes acquisition of Anacor Pharmaceuticals
The Anacor acquisition adds crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, to Pfizer's pipeline...
news
NICE recommends five drugs to treat four different conditions
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS.
news
Enstilar launches in the UK for patients with plaque psoriasis
Enstilar is the first fixed-combination, cutaneous foam spray for the once-daily topical treatment of all extents of plaque psoriasis...
news
EC approves Gazyvaro plus bendamustine in follicular lymphoma
The European Commission has approved Roche’s Gazyvaro (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma.
news
LixiLan-O and LixiLan-L meet primary endpoints
Results from Sanofi’s Phase III LixiLan-O and LixiLan-L clinical trials have been presented at the American Diabetes Association 76th Scientific Sessions.
news
New data for baricitinib in rheumatoid arthritis presented at EULAR
Lilly and Incyte have announced new data for baricitinib in rheumatoid arthritis (RA) at the Annual European Congress of Rheumatology (EULAR 2016).
news
Researchers develop technology for printed personalised medicine
Researchers from the National University of Singapore have found a way to make personalised medicine cheaper and easier.
news
SMC says ‘no’ to Kalydeco and Orkambi in cystic fibrosis
The Scottish Medicines Consortium (SMC) has rejected Kalydeco (ivacaftor) and Orkambi (lumacaftor-ivacaftor) for the treatment of cystic fibrosis.
news
3BNC117 opens door to potential new treatment for HIV
Researchers are developing a new kind of treatment, an antibody-based drug called 3BNC117, that may provide a better strategy for long-term control of HIV...
news
NICE recommends adalimumab for hidradenitis suppurativa
The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Humira (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adult patients with an inadequate response to conventional systemic HS therapy.
news
ProStrakan rebrands as Kyowa Kirin International PLC
Kyowa Hakko Kirin (KHK), the company that acquired ProStraken in 2011, has decided that its western pharmaceutical subsidiaries are to adopt the Kyowa Kirin name...
news
Lilly and Incyte announce results from RA-BEACON baricitinib study
Lilly and Incyte have announced results from the RA-BEACON Phase III study of baricitinib for the treatment of moderate-to-severe rheumatoid arthritis (RA).
news
NICE says ‘no’ to cystic fibrosis drug Orkambi in draft guidance
The National Institute for Health and Care Excellence (NICE) has issued draft guidance which does not recommend Vertex Pharmaceuticals’ Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis.
news
GSK presents data on of Nucala in asthma patients stratified by eosinophil levels
The post-hoc analysis confirms the predictive nature of the relationship between baseline blood eosinophil counts and efficacy outcomes in patients treated with mepolizumab...
